Abstract:Introduction: In the path to clinic, researchers require robust tools to effectively evaluate the capacity of novel therapeutic modalities to generate anti-tumor responses. Using human-relevant, translational ex-vivo models is widely considered to reduce attrition during drug discovery and development for a more effective prediction of clinical outcomes during preclinical testing of drug candidates. Methods: The three levels of our patient derived tumoroid model platform, COMPASS (Custom Organoid Modeling Platform for Accurate SolutionS) was built to be versatile modality-agnostic human on human model system for pre-clinical testing. COMPASS 1 has stroma with epithelium; COMPASS 2 has stroma, epithelium, and immune components (from PBMCs) and COMPASS 3 has stroma, epithelium, immune components, and oxygenation. For widespread adaptation and utilization of our COMPASS platform we encourage extensive characterization by articulating the context of use to help build confidence in cases where limited knowledge and only few real-life cases exist. Results: Our proof-of-concept examples articulating the context of use demonstrate the modality-agnostic adaptability our COMPASS platform brings to the field of preclinical testing. We encourage a collaborative approach with researchers to support their testing needs to build confidence in our model to enable transition from existing screens, assays, and animal models. We envision preclinical use of COMPASS to help stratify patients for clinical trials, identify subpopulations that need dose modification and predict the response of patients and/or their risk of adverse effects. Conclusion: Due to its greater physiological relevance and ability to encompass downstream processes in a time and cost-efficient way, industry and academia should deliberate the impact platform such as COMPASS would have on their workflow and consider adapting to using these models routinely. Citation Format: Preethi Samuel, Damieanus Odour Ochola, Huckie Del Mundo, Bhuvanesh Dave. Modality agnostic tumor models of cancer which can more accurately define drug efficacy and mechanism to help develop more effective therapeutics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6779.

Complex In Vitro Model Characterization for Context of Use in Toxicologic Pathology: Use Cases by Collaborative Teams of Biologists, Bioengineers, and Pathologists

Complex in Vitro Model: A Transformative Model in Drug Development and Precision Medicine

Pluripotent Stem Cells: an in Vitro Model for Nanotoxicity Assessments

Advanced Tissue Technologies of Blood-Brain Barrier Organoids as High Throughput Toxicity Readouts in Drug Development

Development of novel tools for the in vitro investigation of drug-induced liver injury

Toxicologic Pathology Forum Opinion Piece: Use of Virtual Control Groups in Nonclinical Toxicity Studies: The Anatomic Pathology Perspective

Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety

Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing

Virtual Control Groups in Non-clinical Toxicity Studies: Impacts on Toxicologic Clinical Pathology Data Interpretation

Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives

The Frontline of Alternatives to Animal Testing: Novel in Vitro Skin Model Application in Drug Development and Evaluation.

Insect in vitro System for Toxicology Studies - Current and Future Perspectives

IHI VICT3R: Developing and Implementing Virtual Control Groups to Reduce Animal Use in Toxicology Research

Transforming Toxicity Assessment through Microphysiology, Bioprinting, and Computational Modeling

Advancing Environmental Toxicology In Vitro: From Immortalized Cancer Cell Lines to 3D Models Derived from Stem Cells

Perspectives on In Vitro to In Vivo Extrapolations

The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development

In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research

Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment

Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends

Abstract 6779: Modality agnostic tumor models of cancer which can more accurately define drug efficacy and mechanism to help develop more effective therapeutics